MedTrace Logo

Maternal Transcriptomic Regulation of the Preimplantation Embryo

NCT02813746 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2016-06-28

No results posted yet for this study

Summary

The aim of this study is to understand the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD), either for the presence of metabolic disorders in the future mothers, such as obesity or for the exposure to certain contaminants such as tobacco.

To do that, the miRNAs profiles secreted to the endometrial fluid in obese women vs normoweight women during the window of implantation will be identified. Likewise, it will be studied how that miRNA signature is normalized once a substantial loss of weight is produced by the patients involved in the studied. In parallel, a comparison of the miRNA expression profiles secreted in the endometrial fluid in smoker women vs nonsmoker women will be performed. As in the previous case, it will be studied if after the exposure to these contaminant, the normalization of the miRNA expression signature occurs. Finally, an in silico analysis will be carried out in order to define the target genes and the metabolic pathways affected by the miRNAs profile secreted in both pathological conditions

Conditions

  • Fetal Origin of Adult Diseases

Interventions

DIETARY_SUPPLEMENT

Fitness program

BEHAVIORAL

Stop smoking

PROCEDURE

Endometrial fluid collection

Sponsors & Collaborators

  • Igenomix

    lead INDUSTRY

Principal Investigators

  • Carlos Simón, MD PhD · Igenomix

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-04-30
Completion
2019-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02813746 on ClinicalTrials.gov